← Back to Search

CAR T-cell Therapy

CART-ddBCMA for Multiple Myeloma (iMMagine-1 Trial)

Phase 2

Recruiting

Research Sponsored by Kite, A Gilead Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

iMMagine-1 Trial Summary

This trial is testing a new cancer treatment that uses a patient's own immune cells to target and destroy cancer cells.

Who is the study for?

Adults with relapsed or refractory multiple myeloma who have tried at least three prior treatments, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. They must show measurable disease signs, be in good physical condition (ECOG 0-1), have a life expectancy over 12 weeks, and proper organ function. Participants should not be pregnant or breastfeeding and must agree to use effective birth control for a year post-treatment.Check my eligibility

What is being tested?

The trial is testing CART-ddBCMA, which is a type of CAR-T cell therapy targeting BCMA on cancer cells. It's for patients whose multiple myeloma has returned after treatment or hasn't responded to standard therapies. The study will assess the safety and effectiveness of this new intervention.See study design

What are the potential side effects?

CAR-T cell therapies like CART-ddBCMA can cause cytokine release syndrome (flu-like symptoms such as fever and fatigue), neurological effects (confusion or difficulty speaking), low blood cell counts leading to increased infection risk, bleeding issues, and potential allergic reactions.

iMMagine-1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Response Rate (ORR)

Secondary outcome measures

Anti-anitocabtagene-autoleucel Antibodies

Duration of Response (DoR)

Health Related Quality of Life (HRQoL)

+10 more

iMMagine-1 Trial Design

1Treatment groups

Experimental Treatment

Group I: anitocabtagene-autoleucelExperimental Treatment1 Intervention

Single dose of 115±10 x 10e-6 CAR+ anitocabtagene-autoleucel cells infused intravenously

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Multiple Myeloma Research FoundationOTHER

10 Previous Clinical Trials

3,467 Total Patients Enrolled

10 Trials studying Multiple Myeloma

3,467 Patients Enrolled for Multiple Myeloma

Kite, A Gilead CompanyLead Sponsor

43 Previous Clinical Trials

3,546 Total Patients Enrolled

3 Trials studying Multiple Myeloma

98 Patients Enrolled for Multiple Myeloma

Arcellx, Inc.Industry Sponsor

2 Previous Clinical Trials

89 Total Patients Enrolled

1 Trials studying Multiple Myeloma

65 Patients Enrolled for Multiple Myeloma

Media Library

CART-ddBCMA (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05396885 — Phase 2

Multiple Myeloma Research Study Groups: anitocabtagene-autoleucel

Multiple Myeloma Clinical Trial 2023: CART-ddBCMA Highlights & Side Effects. Trial Name: NCT05396885 — Phase 2

CART-ddBCMA (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05396885 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks associated with CART-ddBCMA treatment?

"CART-ddBCMA falls into the category of a Phase 2 trial, which means that while there is some evidence supporting its safety, none exists for its efficacy. Therefore, it received a score of 2."

Answered by AI

Are individuals with the relevant medical condition able to enroll in this trial at this time?

"According to the latest update on clinicaltrials.gov, this study is not currently looking for new participants. This trial was first posted on July 15th, 2022 and was last updated on July 7th, 2022. 827 other trials are actively recruiting patients right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

2022. "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05396885.